曲美他嗪联合卡维地洛对高血压心脏病慢性心力衰竭患者的影响

目的探讨曲美他嗪联合卡维地洛对高血压心脏病慢性心力衰竭患者的影响情况。方法分析我院2016年1月~2017年6月内科收治的100例高血压心脏病慢性心力衰竭患者临床资料,依据治疗方式不同进行分组,对照组(卡维地洛治疗)50例和联合治疗组(曲美他嗪联合卡维地洛治疗)50例,观察两组患者治疗前后左室射血分数(Left ventricular ejection fractions,LVEF)、左室舒张末期容积(Left ventricular end diastolic diameter,LVEDD)、左室收缩末期容积(left-ventricular end systolic volume,LVESD)、6 min步行距离(6-min walking distance,6MWD)、血浆氨基末端脑钠肽前体(N-terminal pro-brain natriuretic peptide,NT-pro BNP)、心肌钙蛋白(cardiac troponin I,cTnI)、脂联素(adiponectin,APN)、纤维蛋白原(fibrirlogerl,FG)、甘油三酯(Triglyceride,TG)、总胆固醇(Total cholesterol,TC)、高密度脂蛋白胆固醇(High-density lipoprotein cholesterol,HDL-C)、低密度脂蛋白胆固醇(Lowdensity lipoprotein cholesterol,LDL-C)情况,观察两组患者临床疗效情况。结果两组患者治疗前LVEF、LVEDD、LVESD、6MWD、NT-pro BNP、cTnI、APN、FG、TG、TC、HDL-C、LDL-C比较,差异均无统计学意义(P0.05),治疗后对照组和联合治疗组LVEF、6MWD、HDL-C均高于治疗前,NT-pro BNP、cTnI、APN、FG、LVEDD、LVESD、TG、TC、LDL-C均低于治疗前,联合治疗组治疗后LVEF、6MWD、HDL-C均高于对照组,NT-pro BNP、cTnI、APN、FG、LVEDD、LVESD、TG、TC、LDL-C均低于对照组,联合治疗组患者临床治疗总有效率高于对照组,差异有统计学意义(P0.05)。结论曲美他嗪联合卡维地洛治疗高血压心脏病慢性心力衰竭患者,可以提高心功能,改善心衰敏感指标,降低血脂水平,提高临床效果,值得临床推广应用。

Effect of trimetazidine combined with carvedilol on hypertension heart disease patients with chronic heart failure

Objective To investigate the effect of trimetazidine combined with carvedilol on hypertension heart disease patients with chronic heart failure. Methods The clinical data of 100 patients with chronic heart failure with hypertension heart disease admitted tin our hospital from January 2016 to June 2017 were analyzed. The patients were grouped according to different treatment methods, including control group(n=50) treated with carvedilol treatment and combination therapy group(n=50) treated with trimetazidine combined with carvedilol. The left ventricular ejection fraction (LVEF),left ventricular end diastolic diameter (LVEDD), Left-ventricular end systolic volume (LVESD), 6-min walking distance (6MWD), plasma N-terminal pro-brain natriuretic peptide (NT-pro BNP), cardiac troponin I (cTnI), adiponectin (APN),fibrinogen (FG), triglyceride (TG), total cholesterol (TC), High-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol(LDL-C) were observed before and after treatment. The clinical efficacy of the two groups of patients was observed. Results There was no significant difference in LVEF, LVEDD, LVES, 6MWD, NT-pro BNP,cTnI, APN, FG, TG, TC, HDL-C, LDL-C before treatment between the two groups(P>0.05). The LVEF, 6MWD, and HDL-C in the control and combination treatment groups were higher than those before treatment. The NT-pro BNP,cTnI, APN, FG, LVEDD, LVESD, TG, TC and LDL-C in both groups after treatment were lower than those before treatment. The LVEF, 6MWD, and HDL-C were higher in the treatment group than those in the control group after treatment. And the NT-pro BNP, cTnI, APN, FG, LVEDD, LVESD, TG, TC, and LDL-C in the treatment group were lower than those in the control group. The total effective rate of treatment in the treatment group was higher than that of the control group, and the difference was statistically significant(P<0.05). Conclusion Trimetazidine combined with carvedilol in the treatment of hypertension heart disease patients with chronic heart failure can improve heart function,improve the sensitive indicators of heart failure, reduce blood lipid levels and improve clinical efficacy. It is worthy of clinical application.